The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
Open accessAbstract
BACKGROUND: The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause. Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity. METHODS: We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome. Patients were negative for the FIP1L1-PDGFRA fusion gene and required prednisone monotherapy, 20 to 60 mg per day, to maintain a stable clinical status and a blood eosinophil count of less than 1000 per microliter. Patients received either intravenous mepolizumab or placebo while the prednisone dose was tapered. The primary end point was the reduction of the prednisone dose to 10 mg or less per day for 8 or more consecutive weeks. RESULTS: The primary end point was reached in 84% of patients in the mepolizumab group, as compared with 43% of patients in the placebo group (hazard ratio, 2.90; 95% confidence interval [CI], 1.59 to 5.26; P<0.001) with no increase in clinical activity of the hypereosinophilic syndrome. A blood eosinophil count of less than 600 per microliter for 8 or more consecutive weeks was achieved in 95% of patients receiving mepolizumab, as compared with 45% of patients receiving placebo (hazard ratio, 3.53; 95% CI, 1.94 to 6.45; P<0.001). Serious adverse events occurred in seven patients receiving mepolizumab (14 events, including one death; mean [+/-SD] duration of exposure, 6.7+/-1.9 months) and in five patients receiving placebo (7 events; mean duration of exposure, 4.3+/-2.6 months). CONCLUSIONS: Our study shows that treatment with mepolizumab, an agent designed to target eosinophils, can result in corticosteroid-sparing for patients negative for FIP1L1-PDGFRA who have the hypereosinophilic syndrome. (ClinicalTrials.gov number, NCT00086658 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Leckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Rothenberg, M. E., & Hogan, S. P. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090720 · Cited by 1,356
Self-citationThe hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.
Chusid, M. J., Dale, D. C., West, B. C., & Wolff, S. M. (1975) · PubMed · Cited by 1,233
THE HYPEREOSINOPHILIC SYNDROME: Analysis of Fourteen Cases With Review of The Literature
CHUSID, M. J., DALE, D. C., WEST, B. C., & WOLFF, S. M. (1975) · Medicine · doi:10.1097/00005792-197501000-00001 · Cited by 1,078
Interleukin-5, eosinophils, and disease
Sanderson, C. (1992) · Blood · doi:10.1182/blood.v79.12.3101.3101 · Cited by 976
Recombinant human interleukin 5 is a selective activator of human eosinophil function.
Lopez, A. F., Sanderson, C. J., Gamble, J. R., Campbell, H. D., Young, I. G., & Vadas, M. A. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.1.219 · Cited by 951
Flood-Page, P. T., Menzies-Gow, A. N., Kay, A. B., & Robinson, D. S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-789oc · Cited by 808
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730
Clutterbuck, E., Hirst, E., & Sanderson, C. (1989) · Blood · doi:10.1182/blood.v73.6.1504.1504 · Cited by 687
Pardanani, A., Ketterling, R. P., Brockman, S. R., Flynn, H. C., Paternoster, S. F., Shearer, B. M., Reeder, T. L., Li, C.-Y., Cross, N. C. P., Cools, J., et al. (2003) · Blood · doi:10.1182/blood-2003-05-1627 · Cited by 393
Anti–interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes
Garrett, J. K., Jameson, S. C., Thomson, B., Collins, M. H., Wagoner, L. E., Freese, D. K., Beck, L. A., Boyce, J. A., Filipovich, A. H., Villanueva, J. M., et al. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.10.049 · Cited by 362
Self-citationSystemic corticosteroid therapy---side effects and their management
STANBURY, R. M., & GRAHAM, E. M. (1998) · British Journal of Ophthalmology · doi:10.1136/bjo.82.6.704 · Cited by 348
Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report
Klion, A. D., Bochner, B. S., Gleich, G. J., Nutman, T. B., Rothenberg, M. E., Simon, H.-U., Wechsler, M. E., Weller, P. F., & the Hypereosinophilic Syndromes Working Group (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.02.042 · Cited by 342
Self-citationOldhoff, J. M., Darsow, U., Werfel, T., Katzer, K., Wulf, A., Laifaoui, J., Hijnen, D. J., Plötz, S., Knol, E. F., Kapp, A., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00791.x · Cited by 339
Self-citationEosinophils and atopic dermatitis
Simon, D., Braathen, L. R., & Simon, H. ‐. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00476.x · Cited by 325
Self-citationMenzies-Gow, A., Flood-Page, P., Sehmi, R., Burman, J., Hamid, Q., Robinson, D. S., Kay, A. B., & Denburg, J. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.1382 · Cited by 276
Use of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis
Plötz, S.-G., Simon, H.-U., Darsow, U., Simon, D., Vassina, E., Yousefi, S., Hein, R., Smith, T., Behrendt, H., & Ring, J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031261 · Cited by 259
Self-citationHart, T. K., Cook, R. M., Zia-Amirhosseini, P., Minthorn, E., Sellers, T. S., Maleeff, B. E., Eustis, S., Schwartz, L. W., Tsui, P., Appelbaum, E. R., et al. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.116576 · Cited by 238
Self-citationKlion, A. D., Law, M. A., Noel, P., Kim, Y.-J., Haverty, T. P., & Nutman, T. B. (2004) · Blood · doi:10.1182/blood-2003-10-3620 · Cited by 162
Self-citationMonoclonal anti-interleukin‐5 treatment suppresses eosinophil but not T‐cell functions
Büttner, C., Lun, A., Splettstoesser, T., Kunkel, G., & Renz, H. E. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00027302 · Cited by 120
Hypereosinophilic syndrome: An update
Wilkins, H. J., Crane, M. M., Copeland, K., & Williams, W. V. (2005) · American Journal of Hematology · doi:10.1002/ajh.20423 · Cited by 109
Phipps, S., Flood-Page, P. T., Menzies-Gow, A. N., Ong, Y. E., & Kay, A. B. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22619.x · Cited by 100
Schrezenmeier, H., Sd, T., Tewald, F., Fleischer, B., & Raghavachar, A. (1993) · PubMed · Cited by 55
Hypereosinophilic Syndrome: Lymphoproliferative and Myeloproliferative Variants
Roufosse, F. E., Goldman, M., & Cogan, E. (2006) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2006-939519 · Cited by 42
Self-citationThe hypereosinophilic syndromes: still more heterogeneity
Gleich, G. J., & Leiferman, K. M. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.09.008 · Cited by 42
Self-citationAnti-IL-5 and hypereosinophilic syndromes
SUTTON, S., ASSAAD, A., & ROTHENBERG, M. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.02.006 · Cited by 40
Self-citationResponses to access block in Australia: Royal North Shore Hospital
Hammett, R. J. H., & Robinson, B. G. (2003) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05095.x · Cited by 21
Cited by
IgE, mast cells, basophils, and eosinophils
Stone, K. D., Prussin, C., & Metcalfe, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.017 · Cited by 1,680
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O'Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,356
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Wechsler, M. E., Akuthota, P., Jayne, D., Khoury, P., Klion, A., Langford, C. A., Merkel, P. A., Moosig, F., Specks, U., Cid, M. C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702079 · Cited by 1,094
Self-citationType 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055
Metadata
- Authors
- Rothenberg, M. E., Klion, A. D., Roufosse, F. E., Kahn, J. E., Weller, P. F., Simon, H.-U., Schwartz, L. B., Rosenwasser, L. J., Ring, J., Griffin, E. F., Haig, A. E., Frewer, P. I. H., Parkin, J. M., & Gleich, G. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-03-20
- Volume
- 358
- Issue
- 12
- Pages
- 1215-1228
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2155730304
- Cited by
- 583
- References
- 28
- FWCI
- 33.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.